Skip to content
HomeLatest newsInnovationDiversifying our health workforce through the impact of AIM
Collage of 2021 AIM Scholars

Diversifying our health workforce through the impact of AIM

Johnson & Johnson and National Medical Fellowships (NMF) celebrate completing the inaugural cohort’s first year of the innovative three-year service-learning program. In alignment with Our Race to Health Equity (ORTHE), the program exposes diverse medical students to medical professionals within pharmaceutical medicine and equips them with the skills and support needed to address health disparities.

In the fall of 2021, 20 high-performing underrepresented medical students from across the country were selected to participate in the inaugural cohort of the Alliance for Inclusion in Medicine (AIM) Scholarship program. In addition to scholarship funding, the program provides Black, Indigenous and People of Color (BIPOC) medical students with the unique opportunity to receive guidance and career insights from Johnson & Johnson physician mentors who provide support for the scholars as they navigate a career in medicine and aspire to address healthcare’s structural and systemic barriers that disproportionately affect communities of color.

Addressing health inequities is a daunting challenge, but through the ORTHE commitment, Johnson & Johnson envisions creating a lasting impact through the change agents and future healthcare leaders of tomorrow. This meaningful collaboration and partnership between Johnson & Johnson and NMF has had tangible outcomes for the fellows who have dedicated their time and effort to become advocates for health equity through their work. These scholars and future cohorts of scholars will go on to treat countless patients. They will help improve the lives of patients through a lens of health equity, social justice, and racial justice. As they grow in their careers, they will be able to share their insights learned through their training and expertise from Johnson & Johnson physicians with colleagues in various healthcare settings.

Thus, the breadth and scope of the impact of AIM are boundless, and the first year of scholars’ experience has been breathtaking!

Along with mentorship support, scholars participated in engaging learning sessions on topics including drug development, drug safety, statistics, real-world evidence, scientific publications, clinical trial protocols, epidemiology and more. These learning sessions taught scholars the essential skills to make lasting improvements to healthcare systems that best serve diverse patient populations. Scholars also shared how the program strengthened their commitment to pursue a medical career where prioritizing diversity and providing first-class care to historic and presently marginalized BIPOC patients is at the center of their work.

As they continue their journey to becoming the healthcare leaders of tomorrow, we look forward to seeing the incredible impact these exceptional scholars will have in their communities and the patients they serve. Stay tuned as we get ready to welcome the AIM program’s second cohort of scholars in the coming months!

Look through these scholar reflection quote cards to find out how these exceptional medical students are working towards mitigating health inequities.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.